<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="3.0" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id>
<journal-id journal-id-type="publisher-id">plos</journal-id>
<journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group>
<journal-title>PLoS ONE</journal-title></journal-title-group>
<issn pub-type="epub">1932-6203</issn>
<publisher>
<publisher-name>Public Library of Science</publisher-name>
<publisher-loc>San Francisco, USA</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">PONE-D-13-36795</article-id>
<article-id pub-id-type="doi">10.1371/journal.pone.0082858</article-id>
<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories>
<title-group>
<article-title>Association of <italic>TLR2</italic> and <italic>TLR4</italic> Polymorphisms with Risk of Cancer: A Meta-Analysis</article-title>
<alt-title alt-title-type="running-head"><italic>TLR2</italic> and <italic>TLR4</italic> Polymorphisms and Risk of Cancer</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Zhu</surname><given-names>Longbiao</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" equal-contrib="yes" xlink:type="simple"><name name-style="western"><surname>Yuan</surname><given-names>Hua</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Jiang</surname><given-names>Tao</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>Ruixia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Ma</surname><given-names>Hongxia</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
<contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>Shuangyue</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib>
</contrib-group>
<aff id="aff1"><label>1</label><addr-line>Institute of Stomatology, Nanjing Medical University, Nanjing, China</addr-line></aff>
<aff id="aff2"><label>2</label><addr-line>Section of Clinical Epidemiology, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Cancer Center, Nanjing Medical University, Nanjing, China</addr-line></aff>
<aff id="aff3"><label>3</label><addr-line>Department of Epidemiology and Biostatistics, MOE Key Laboratory of Modern Toxicology, School of Public Health, Nanjing Medical University, Nanjing, China</addr-line></aff>
<aff id="aff4"><label>4</label><addr-line>Central Lab, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, China</addr-line></aff>
<contrib-group>
<contrib contrib-type="editor" xlink:type="simple"><name name-style="western"><surname>Miao</surname><given-names>Xiaoping</given-names></name>
<role>Editor</role>
<xref ref-type="aff" rid="edit1"/></contrib>
</contrib-group>
<aff id="edit1"><addr-line>MOE Key Laboratory of Environment and Health, Huazhong University of Science and Technology, China</addr-line></aff>
<author-notes>
<corresp id="cor1">* E-mail: <email xlink:type="simple">mahongxia927@gmail.com</email> (HM); <email xlink:type="simple">zsy2005edu@sina.com</email> (SZ)</corresp>
<fn fn-type="conflict"><p>The authors have declared that no competing interests exist.</p></fn>
<fn fn-type="con"><p>Conceived and designed the experiments: HM SZ. Performed the experiments: LZ HY. Analyzed the data: HY TJ RW. Contributed reagents/materials/analysis tools: HM SZ. Wrote the paper: LZ HY.</p></fn>
</author-notes>
<pub-date pub-type="collection"><year>2013</year></pub-date>
<pub-date pub-type="epub"><day>20</day><month>12</month><year>2013</year></pub-date>
<volume>8</volume>
<issue>12</issue>
<elocation-id>e82858</elocation-id>
<history>
<date date-type="received"><day>6</day><month>9</month><year>2013</year></date>
<date date-type="accepted"><day>29</day><month>10</month><year>2013</year></date>
</history>
<permissions>
<copyright-year>2013</copyright-year>
<copyright-holder>Zhu et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This is an open-access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/" xlink:type="simple">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions>
<abstract><sec>
<title>Backgrounds</title>
<p>The activation of Toll-like receptors (TLRs) may be an important event in the immune evasion of tumor cell. Recently, numerous studies have investigated the associations between <italic>TLR2</italic> −196 to −174 del and two SNPs of <italic>TLR4</italic> (rs4986790 and rs4986791) and the susceptibility to different types of cancer; however, the results remain conflicting. The aim of this study was to assess the association between <italic>TLR2</italic> and <italic>TLR4</italic> polymorphisms and cancer risk in a meta-analysis with eligible published studies.</p>
</sec><sec>
<title>Methodology/Principle Findings</title>
<p>A dataset composed of 14627 cases and 17438 controls from 34 publications were included in a meta-analysis to evaluate the association between overall cancer risk or cancer-specific risk and three SNPs of <italic>TLRs</italic> (<italic>TLR2</italic> −196 to −174 del, <italic>TLR4</italic> rs4986790 and rs4986791). The results showed that all of these three polymorphisms were significantly associated with the increased cancer risk (dominant model: OR = 1.64, 95% CI: 1.04–2.60 for <italic>TLR2</italic> −196 to −174 del; OR = 1.19, 95% CI: 1.01–1.41 for <italic>TLR4</italic> rs4986790; and OR = 1.47, 95% CI: 1.120–1.80 for <italic>TLR4</italic> rs4986791; respectively). In stratified analysis, we found the effect of <italic>TLR2</italic> −196 to −174 del on cancer risk remained significant in the subgroup of Caucasians and South Asians, but not in East Asians. However, the association between rs4986791 and cancer risk was significant in both South Asians and East Asians, but not in Caucasians. Furthermore, the association between rs4986790 and cancer risk was statistically significant in digestive cancers (dominant model: OR = 1.76, 95% CI: 1.13–2.73) and female-specific cancers (dominant model: OR = 1.50, 95% CI: 1.16–1.94). However, no significant association with risk of digestive system cancers was observed for <italic>TLR2</italic> −196 to −174 del and <italic>TLR4</italic> rs4986791.</p>
</sec><sec>
<title>Conclusions/Significance</title>
<p>This meta-analysis presented additional evidence for the association between <italic>TLR2</italic> and <italic>TLR4</italic> polymorphisms and cancer risk. Further well-designed investigations with large sample sizes are required to confirm this conclusion.</p>
</sec></abstract>
<funding-group><funding-statement>This work was supported in part by National Natural Science Foundation of China (81270044 and 81302361), Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), Jiangsu Natural Science Foundation (BK2011764) and Jiangsu Province Clinical Science and Technology Projects (BL2012008). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="9"/></counts></article-meta>
</front>
<body><sec id="s1">
<title>Introduction</title>
<p>Toll-like receptors (TLRs) are a family of membrane-spanning innate immune receptors that recognize ligands derived from bacteria, fungi, viruses, and parasite <xref ref-type="bibr" rid="pone.0082858-Kawai1">[1]</xref>. TLRs play a key role in the realization of innate and adaptive immune response, being involved in the regulation of inflammatory reactions and activation of the adaptive immune response to eliminate infectious pathogens and cancer debris <xref ref-type="bibr" rid="pone.0082858-Iwasaki1">[2]</xref>, <xref ref-type="bibr" rid="pone.0082858-Wang1">[3]</xref>. Besides driving inflammatory responses, TLRs also regulate cell proliferation and survival by expanding useful immune cells and integrating inflammatory responses and tissue repair processes <xref ref-type="bibr" rid="pone.0082858-Basith1">[4]</xref>. Furthermore, functional TLRs are expressed not only in immune cells, but also in cancer cells, thus implicating a role of TLRs in tumor biology <xref ref-type="bibr" rid="pone.0082858-Takeda1">[5]</xref>, <xref ref-type="bibr" rid="pone.0082858-Aderem1">[6]</xref>. Increasing bodies of evidence have suggested that TLRs can act as a double-edged sword in cancer cells because uncontrolled TLR signaling provides a microenvironment that is necessary for tumor cells to proliferate and evade the immune response <xref ref-type="bibr" rid="pone.0082858-Basith1">[4]</xref>, <xref ref-type="bibr" rid="pone.0082858-Drexler1">[7]</xref>. In addition, activation of TLRs not only leads to the up-regulation of cellular defense mechanisms, but also results in up-regulation of DNA repair genes and increased functional DNA repair <xref ref-type="bibr" rid="pone.0082858-Menendez1">[8]</xref>, <xref ref-type="bibr" rid="pone.0082858-Harberts1">[9]</xref>.</p>
<p>The TLR family includes 2 subgroups, extracellular and intracellular, depending on their cellular localization. TLR1, 2, 5, 6 and 10 are extracellular TLRs, which are largely localized on the cell surface. Conversely, TLR3, 7, 8 and 9 (intracellular TLRs) are localized in intracellular organelles. The subcellular localization of <italic>TLR4</italic> is unique because it is localized to both the plasma membrane and endosomal vesicles <xref ref-type="bibr" rid="pone.0082858-Kagan1">[10]</xref>. <italic>TLR2</italic> and <italic>TLR4</italic> are major TLRs and have been actively investigated in inflammation and cancer. There is evidence that <italic>TLRs</italic>, particularly <italic>TLR2</italic> and <italic>TLR4</italic>, directly regulate major proinflammatory and host defense functions of human neutrophils <xref ref-type="bibr" rid="pone.0082858-Sabroe1">[11]</xref>. Additionally, <italic>TLR2</italic> recognizes microbial pathogen-associated molecular patterns, such as cell wall peptidoglycan and lipoteichoic acid <xref ref-type="bibr" rid="pone.0082858-Takeuchi1">[12]</xref>. Positive <italic>TLR2</italic> expression in the tumor microenvironment suggests that immune surveillance is activated against the altered epithelial cells, whereas <italic>TLR2</italic> expression by malignant keratinocytes may be indicative of resistance to apoptosis as a prosurvival mechanism <xref ref-type="bibr" rid="pone.0082858-Huang1">[13]</xref>. <italic>TLR4</italic> ligation on tumor cells can enhance the secretion of immunosuppressive cytokines and induce resistance to TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis <xref ref-type="bibr" rid="pone.0082858-Chen1">[14]</xref>, <xref ref-type="bibr" rid="pone.0082858-He1">[15]</xref>. Studies have shown that lipopolysaccharide (LPS) ligation to <italic>TLR4</italic> promotes tumor cell adhesion and invasion in a murine model by acting NF-kappa B <xref ref-type="bibr" rid="pone.0082858-Wang2">[16]</xref>, and the silencing of <italic>TLR4</italic> increases tumor progression and metastasis in a murine model of breast cancer <xref ref-type="bibr" rid="pone.0082858-Ahmed1">[17]</xref>.</p>
<p>Genetic studies have identified a polymorphism of <italic>TLR2</italic> that causes a 22-bp nucleotide deletion (−196 to −174 del) in the promoter region, which may influence the promoter activity of <italic>TLR2</italic> and lead to the decreased transcription of <italic>TLR2</italic> gene. Additionally, two SNPs in <italic>TLR4</italic> have also been identified; one is an A→G substitution at 896 base pair (bp) which results in an aspartic acid to glycine replacement at the codon 299 (D299G, rs4986790) and the other is a C→T substitution at 1196 bp which results in a threonine to isoleucine exchange at codon 399 (T399I, rs4986791). It has been shown that these two polymorphisms (rs4986790 and rs4986791) affect the extracellular domain of the receptor and may cause decreased ligand recognition <xref ref-type="bibr" rid="pone.0082858-Ferwerda1">[18]</xref>. The associations of these three polymorphisms with cancer risk have been widely studied, including bladder cancer <xref ref-type="bibr" rid="pone.0082858-Singh1">[19]</xref>, <xref ref-type="bibr" rid="pone.0082858-Shen1">[20]</xref>, breast cancer <xref ref-type="bibr" rid="pone.0082858-Theodoropoulos1">[21]</xref>, <xref ref-type="bibr" rid="pone.0082858-Etokebe1">[22]</xref>, gastric cancer <xref ref-type="bibr" rid="pone.0082858-deOliveira1">[23]</xref>–<xref ref-type="bibr" rid="pone.0082858-Hold1">[31]</xref>, prostate cancer <xref ref-type="bibr" rid="pone.0082858-Mandal1">[32]</xref>–<xref ref-type="bibr" rid="pone.0082858-Cheng1">[37]</xref>, hepatocellular cancer <xref ref-type="bibr" rid="pone.0082858-Nischalke1">[38]</xref>, <xref ref-type="bibr" rid="pone.0082858-Agundez1">[39]</xref>, gallbladder cancer <xref ref-type="bibr" rid="pone.0082858-Srivastava1">[40]</xref>, cervical cancer <xref ref-type="bibr" rid="pone.0082858-Pandey1">[41]</xref>, nasopharyngeal cancer <xref ref-type="bibr" rid="pone.0082858-Yang1">[42]</xref>, leukemia <xref ref-type="bibr" rid="pone.0082858-Miedema1">[43]</xref>, melanoma <xref ref-type="bibr" rid="pone.0082858-Gast1">[44]</xref>, endometrial cancer <xref ref-type="bibr" rid="pone.0082858-Ashton1">[45]</xref>, lymphoma <xref ref-type="bibr" rid="pone.0082858-Purdue1">[46]</xref>–<xref ref-type="bibr" rid="pone.0082858-Hellmig1">[50]</xref>, esophageal cancer <xref ref-type="bibr" rid="pone.0082858-Hold1">[31]</xref> and colorectal cancer <xref ref-type="bibr" rid="pone.0082858-BoraskaJelavic1">[51]</xref>, <xref ref-type="bibr" rid="pone.0082858-Landi1">[52]</xref>. However, the results remained inconsistent rather than conclusive.</p>
<p>Considering the relatively small sample size in each single study might have low power to detect the effect of the polymorphisms on cancer risk and the underlying heterogeneity among different studies need be explored, we conducted a meta-analysis on all eligible published case-control studies to establish a relatively comprehensive picture of the relationship between these genetic variants (−196 to −174 del in <italic>TLR2</italic>, rs4986790 and rs4986791 in <italic>TLR4</italic>) and cancer risk.</p>
</sec><sec id="s2" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="s2a">
<title>Selection Criteria and Identification of Eligible Studies</title>
<p>Candidate studies were identified through computer-aided literature searching in PubMed for relevant articles in English and Chinese (last search was in January, 2013). The following keywords were used for this search: ‘<italic>TLR2</italic> or Toll like receptor 2′ or ‘<italic>TLR4</italic> or Toll like receptor 4′ and ‘cancer’ and ‘polymorphism’. We also included additional studies by a hands-on search of references of original studies. Abstracts, case-only articles, editorials, review articles and repeated literatures were excluded. The inclusion criteria of studies in the current meta-analysis were defined as follows: (1) original papers containing independent data; (2) case-control design on the association of <italic>TLR2</italic> (−196 to −174 del) or <italic>TLR4</italic> (rs4986790 and rs4986791) polymorphisms and cancer risk; (3) providing sufficient information to calculate the odds ratio (OR) or <italic>P</italic>-value; (4) written in English or Chinese.</p>
</sec><sec id="s2b">
<title>Data Extraction</title>
<p>Two investigators (Zhu LB and Jiang T) independently extracted data and reached a consensus on all items. For each study, the following information was extracted: first author, publication date, country, ethnicity, total number of cases and controls, the numbers of cases and controls grouped by different genotypes and Hardy-Weinberg equilibrium test in control subjects.</p>
</sec><sec id="s2c">
<title>Statistical Analysis</title>
<p>The crude odds ratios (ORs) and 95% confidence intervals (95% CIs) of <italic>TLR2</italic> (−196 to −174 del) and <italic>TLR4</italic> (rs4986790 and rs4986791) polymorphisms and cancer risk were estimated for each study. In addition, we also performed stratification analyses by cancer types and races. Digestive system included gastric, esophageal, colorectal, gallbladder and hepatocellular cancer; blood system included leukemia and lymphoma; female-specific included endometrial, breast and cervical cancer; male-specific included prostate cancer. If one cancer type contained less than three individual studies, they were combined into the ‘other’ group. All subjects were categorized as Caucasian, East Asian (China and Japan), South Asian (India) and mixed. The pooled ORs were performed by allele comparisons and genetic models comparisons. The HWE was assessed via χ<sup>2</sup> test. A Chi-square based Q test and <italic>I<sup>2</sup></italic>-statistic test were performed to assess the potential heterogeneity among the studies <xref ref-type="bibr" rid="pone.0082858-Lau1">[53]</xref>. If the result of heterogeneity test was <italic>p</italic>&gt;0.05, ORs were pooled according to the fixed-effect model <xref ref-type="bibr" rid="pone.0082858-Mantel1">[54]</xref>. Otherwise, the random-effect model was used <xref ref-type="bibr" rid="pone.0082858-DerSimonian1">[55]</xref>. The significance of the pooled ORs was determined by the Z-test. The sensitivity analysis was carried out to test the stability of the pooled effect by excluding each study individually and recalculating the ORs and 95% CI. To further explore the potential sources of heterogeneity among studies, meta regression was performed with some study characteristics, including ethnicity, genotyping methods, tumor types, sample size(≥500 or &lt;500), minor allele frequency (MAF) in control subjects, and source of controls (population-based or hospital-based). Additionally, the inverted funnel plots and Begg’s funnel plot were used to evaluate publication bias <xref ref-type="bibr" rid="pone.0082858-Begg1">[56]</xref>. The statistical analyses were performed by STATA 12.0 software. All <italic>P</italic> values were two-sided.</p>
</sec></sec><sec id="s3">
<title>Results</title>
<sec id="s3a">
<title>Characteristics of Studies</title>
<p>115 articles were initially identified. Among them, 70 papers did not meet our criteria and were excluded. After reading the full texts of the remaining 45 papers, we found 10 papers had not enough genotype data and 1 paper was a review. Therefore, a total of 34 publications including 51 studies were remained (<xref ref-type="fig" rid="pone-0082858-g001">Figure 1</xref>). All studies were of case-control design, including fourteen kinds of cancers. Among them, 10 case-control studies focused on <italic>TLR2</italic> −196 to −174 del (2521 cases and 3247 controls), 27 on <italic>TLR4</italic> rs4986790 (9743 cases and 10839 controls), and 14 on <italic>TLR4</italic> rs4986791 (2363 cases and 3352 controls). Moreover, three publications focused on all three SNPs, ten publications focused on two SNPs, and twenty-one publications focused on only one SNP of all. The detailed characteristics of these studies, including first author, year of publication, country, ethnicity, cancer type, numbers of cases and controls, minor allele frequency (MAF) and HWE for all studies were summarized in <xref ref-type="table" rid="pone-0082858-t001">Table 1</xref>. The distribution of genotypes in the controls of the studies was all in agreement with HWE except for four studies <xref ref-type="bibr" rid="pone.0082858-Shen1">[20]</xref>, <xref ref-type="bibr" rid="pone.0082858-Chen2">[35]</xref>, <xref ref-type="bibr" rid="pone.0082858-Srivastava1">[40]</xref>, <xref ref-type="bibr" rid="pone.0082858-Yang1">[42]</xref>.</p>
<fig id="pone-0082858-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.g001</object-id><label>Figure 1</label><caption>
<title>Study selection process.</title>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.g001" position="float" xlink:type="simple"/></fig><table-wrap id="pone-0082858-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.t001</object-id><label>Table 1</label><caption>
<title>Characteristics of literatures included in the meta-analysis.</title>
</caption><alternatives><graphic id="pone-0082858-t001-1" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.t001" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Reference</td>
<td align="left" rowspan="1" colspan="1">Year</td>
<td align="left" rowspan="1" colspan="1">Country</td>
<td align="left" rowspan="1" colspan="1">Ethnicity</td>
<td align="left" rowspan="1" colspan="1">Cancer type</td>
<td colspan="3" align="left" rowspan="1">Genotype-case</td>
<td colspan="3" align="left" rowspan="1">Genotype-control</td>
<td align="left" rowspan="1" colspan="1">MAF</td>
<td align="left" rowspan="1" colspan="1">HWE</td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1"><bold><italic>TLR2</italic></bold> −<bold>196 to</bold> −<bold>174 del</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">ins/ins</td>
<td align="left" rowspan="1" colspan="1">ins/del</td>
<td align="left" rowspan="1" colspan="1">del/del</td>
<td align="left" rowspan="1" colspan="1">ins/ins</td>
<td align="left" rowspan="1" colspan="1">ins/del</td>
<td align="left" rowspan="1" colspan="1">del/del</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Singh V<sup>17</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Bladder</td>
<td align="left" rowspan="1" colspan="1">110</td>
<td align="left" rowspan="1" colspan="1">79</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">119</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">0.223</td>
<td align="left" rowspan="1" colspan="1">0.437</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Theodoropoulos GE<sup>19</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Greece</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Breast</td>
<td align="left" rowspan="1" colspan="1">120</td>
<td align="left" rowspan="1" colspan="1">113</td>
<td align="left" rowspan="1" colspan="1">28</td>
<td align="left" rowspan="1" colspan="1">432</td>
<td align="left" rowspan="1" colspan="1">46</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.052</td>
<td align="left" rowspan="1" colspan="1">0.518</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>de Oliveira JG<sup>21</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Brazil</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">116</td>
<td align="left" rowspan="1" colspan="1">50</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">189</td>
<td align="left" rowspan="1" colspan="1">34</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.084</td>
<td align="left" rowspan="1" colspan="1">0.733</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Mandal RK<sup>30</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">135</td>
<td align="left" rowspan="1" colspan="1">54</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">193</td>
<td align="left" rowspan="1" colspan="1">52</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.124</td>
<td align="left" rowspan="1" colspan="1">0.500</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Zeng HM<sup>22</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">119</td>
<td align="left" rowspan="1" colspan="1">110</td>
<td align="left" rowspan="1" colspan="1">19</td>
<td align="left" rowspan="1" colspan="1">187</td>
<td align="left" rowspan="1" colspan="1">246</td>
<td align="left" rowspan="1" colspan="1">63</td>
<td align="left" rowspan="1" colspan="1">0.375</td>
<td align="left" rowspan="1" colspan="1">0.195</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Nischalke HD<sup>36</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="left" rowspan="1" colspan="1">Germany</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Hepatocellular</td>
<td align="left" rowspan="1" colspan="1">115</td>
<td align="left" rowspan="1" colspan="1">63</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">248</td>
<td align="left" rowspan="1" colspan="1">92</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">0.153</td>
<td align="left" rowspan="1" colspan="1">0.649</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hishida A<sup>23</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">243</td>
<td align="left" rowspan="1" colspan="1">267</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">304</td>
<td align="left" rowspan="1" colspan="1">316</td>
<td align="left" rowspan="1" colspan="1">79</td>
<td align="left" rowspan="1" colspan="1">0.339</td>
<td align="left" rowspan="1" colspan="1">0.819</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Srivastava K<sup>38</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Gallbladder</td>
<td align="left" rowspan="1" colspan="1">132</td>
<td align="left" rowspan="1" colspan="1">94</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">163</td>
<td align="left" rowspan="1" colspan="1">87</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.187</td>
<td align="left" rowspan="1" colspan="1"><bold>0.044</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Pandey S<sup>39</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Cervical</td>
<td align="left" rowspan="1" colspan="1">102</td>
<td align="left" rowspan="1" colspan="1">43</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">114</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.123</td>
<td align="left" rowspan="1" colspan="1">0.333</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Tahara T<sup>28</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">Japan</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">126</td>
<td align="left" rowspan="1" colspan="1">112</td>
<td align="left" rowspan="1" colspan="1">51</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">65</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">0.277</td>
<td align="left" rowspan="1" colspan="1">0.182</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold><italic>TLR4</italic></bold><bold> rs4986790</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">AA</td>
<td align="left" rowspan="1" colspan="1">AG</td>
<td align="left" rowspan="1" colspan="1">GG</td>
<td align="left" rowspan="1" colspan="1">AA</td>
<td align="left" rowspan="1" colspan="1">AG</td>
<td align="left" rowspan="1" colspan="1">GG</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Theodoropoulos GE<sup>19</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Greece</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Breast</td>
<td align="left" rowspan="1" colspan="1">201</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">412</td>
<td align="left" rowspan="1" colspan="1">63</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.076</td>
<td align="left" rowspan="1" colspan="1">0.148</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>de Oliveira JG<sup>21</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Brazil</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">154</td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">215</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.022</td>
<td align="left" rowspan="1" colspan="1">0.773</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Yang ZH<sup>40</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Nasopharyngeal</td>
<td align="left" rowspan="1" colspan="1">205</td>
<td align="left" rowspan="1" colspan="1">29</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">250</td>
<td align="left" rowspan="1" colspan="1">33</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0.071</td>
<td align="left" rowspan="1" colspan="1"><bold>0.024</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Shen Y<sup>18</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Bladder</td>
<td align="left" rowspan="1" colspan="1">431</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">519</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.005</td>
<td align="left" rowspan="1" colspan="1"><bold>0.000</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Miedema KG<sup>41</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="left" rowspan="1" colspan="1">Netherlands</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Leukemia</td>
<td align="left" rowspan="1" colspan="1">168</td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">151</td>
<td align="left" rowspan="1" colspan="1">28</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.078</td>
<td align="left" rowspan="1" colspan="1">0.256</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Gast A<sup>42</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2011</td>
<td align="left" rowspan="1" colspan="1">Germany</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Malignant Melanoma</td>
<td align="left" rowspan="1" colspan="1">665</td>
<td align="left" rowspan="1" colspan="1">91</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">659</td>
<td align="left" rowspan="1" colspan="1">73</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">0.054</td>
<td align="left" rowspan="1" colspan="1">0.525</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Ashton KA<sup>43</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Australia</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Endometrial</td>
<td align="left" rowspan="1" colspan="1">163</td>
<td align="left" rowspan="1" colspan="1">25</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">258</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.060</td>
<td align="left" rowspan="1" colspan="1">0.326</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Balistreri CR<sup>31</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">49</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">111</td>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.060</td>
<td align="left" rowspan="1" colspan="1">0.383</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Rigoli L<sup>27</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">42</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">80</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.023</td>
<td align="left" rowspan="1" colspan="1">0.696</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Etokebe GE<sup>20</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">Croatia</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Breast</td>
<td align="left" rowspan="1" colspan="1">110</td>
<td align="left" rowspan="1" colspan="1">20</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">84</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.076</td>
<td align="left" rowspan="1" colspan="1">0.449</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Pandey S<sup>39</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Cervical</td>
<td align="left" rowspan="1" colspan="1">114</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">123</td>
<td align="left" rowspan="1" colspan="1">26</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.093</td>
<td align="left" rowspan="1" colspan="1">0.767</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Purdue MP<sup>44</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">US</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Non-Hodgkin lymphoma</td>
<td align="left" rowspan="1" colspan="1">1195</td>
<td align="left" rowspan="1" colspan="1">133</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1126</td>
<td align="left" rowspan="1" colspan="1">131</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">0.058</td>
<td align="left" rowspan="1" colspan="1">0.055</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Wang MH<sup>32</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">US</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">230</td>
<td align="left" rowspan="1" colspan="1">24</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">216</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.070</td>
<td align="left" rowspan="1" colspan="1">0.235</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Trejo-de la OA<sup>24</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">Mexico</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">34</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">138</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.021</td>
<td align="left" rowspan="1" colspan="1">0.798</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Ture-Ozdemir F<sup>46</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">Greece</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric MALT lymphoma</td>
<td align="left" rowspan="1" colspan="1">38</td>
<td align="left" rowspan="1" colspan="1">18</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">39</td>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.118</td>
<td align="left" rowspan="1" colspan="1">0.341</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Santini D<sup>25</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">159</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">140</td>
<td align="left" rowspan="1" colspan="1">11</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.036</td>
<td align="left" rowspan="1" colspan="1">0.642</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Garza-Gonzalez E<sup>26</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">Mexico</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">72</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">175</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.037</td>
<td align="left" rowspan="1" colspan="1">0.518</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hold GL<sup>29</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">Poland, US</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">414</td>
<td align="left" rowspan="1" colspan="1">79</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">451</td>
<td align="left" rowspan="1" colspan="1">47</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.041</td>
<td align="left" rowspan="1" colspan="1">0.518</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hold GL<sup>29</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">US</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Oesophageal</td>
<td align="left" rowspan="1" colspan="1">97</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">194</td>
<td align="left" rowspan="1" colspan="1">16</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.043</td>
<td align="left" rowspan="1" colspan="1">0.299</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Cheng I<sup>35</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">US</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">439</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">456</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.051</td>
<td align="left" rowspan="1" colspan="1">0.544</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Nieters A<sup>45</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="left" rowspan="1" colspan="1">Germany</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Lymphoma</td>
<td align="left" rowspan="1" colspan="1">590</td>
<td align="left" rowspan="1" colspan="1">84</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">596</td>
<td align="left" rowspan="1" colspan="1">71</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.055</td>
<td align="left" rowspan="1" colspan="1">0.456</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Boraska Jelavic T<sup>49</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="left" rowspan="1" colspan="1">Croatia</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Colorectal</td>
<td align="left" rowspan="1" colspan="1">77</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">84</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.023</td>
<td align="left" rowspan="1" colspan="1">0.827</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Landi S<sup>50</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="left" rowspan="1" colspan="1">Spain</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Colorectal</td>
<td align="left" rowspan="1" colspan="1">251</td>
<td align="left" rowspan="1" colspan="1">31</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">232</td>
<td align="left" rowspan="1" colspan="1">37</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.069</td>
<td align="left" rowspan="1" colspan="1">0.226</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Forrest MS<sup>47</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="left" rowspan="1" colspan="1">US/UK</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Non-hodgkin lymphoma</td>
<td align="left" rowspan="1" colspan="1">794</td>
<td align="left" rowspan="1" colspan="1">106</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">1254</td>
<td align="left" rowspan="1" colspan="1">172</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0.064</td>
<td align="left" rowspan="1" colspan="1">0.969</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Hellmig S<sup>48</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="left" rowspan="1" colspan="1">Germany/Austria</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric MALT lymphoma</td>
<td align="left" rowspan="1" colspan="1">83</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">313</td>
<td align="left" rowspan="1" colspan="1">45</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.063</td>
<td align="left" rowspan="1" colspan="1">0.204</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Chen YC<sup>33</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2005</td>
<td align="left" rowspan="1" colspan="1">USA</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">588</td>
<td align="left" rowspan="1" colspan="1">66</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">605</td>
<td align="left" rowspan="1" colspan="1">59</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.052</td>
<td align="left" rowspan="1" colspan="1"><bold>0.011</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Zheng SL<sup>34</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2004</td>
<td align="left" rowspan="1" colspan="1">Sweden</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">1241</td>
<td align="left" rowspan="1" colspan="1">136</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">693</td>
<td align="left" rowspan="1" colspan="1">79</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.057</td>
<td align="left" rowspan="1" colspan="1">0.103</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold><italic>TLR4</italic></bold><bold> rs4986791</bold></td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">CC</td>
<td align="left" rowspan="1" colspan="1">CT</td>
<td align="left" rowspan="1" colspan="1">TT</td>
<td align="left" rowspan="1" colspan="1">CC</td>
<td align="left" rowspan="1" colspan="1">CT</td>
<td align="left" rowspan="1" colspan="1">TT</td>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Singh V<sup>17</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Bladder</td>
<td align="left" rowspan="1" colspan="1">163</td>
<td align="left" rowspan="1" colspan="1">35</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">173</td>
<td align="left" rowspan="1" colspan="1">26</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.070</td>
<td align="left" rowspan="1" colspan="1">0.983</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Theodoropoulos GE<sup>19</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Greece</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Breast</td>
<td align="left" rowspan="1" colspan="1">253</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">466</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.015</td>
<td align="left" rowspan="1" colspan="1">0.746</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>de Oliveira JG<sup>21</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Brazil</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">165</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">219</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.013</td>
<td align="left" rowspan="1" colspan="1">0.839</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Yang ZH<sup>40</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Nasopharyngeal</td>
<td align="left" rowspan="1" colspan="1">188</td>
<td align="left" rowspan="1" colspan="1">45</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">254</td>
<td align="left" rowspan="1" colspan="1">32</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.059</td>
<td align="left" rowspan="1" colspan="1">0.994</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Agundez JA<sup>37</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">Spain</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Hepatocellular</td>
<td align="left" rowspan="1" colspan="1">143</td>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">341</td>
<td align="left" rowspan="1" colspan="1">47</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.065</td>
<td align="left" rowspan="1" colspan="1">0.783</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Shen Y<sup>18</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2012</td>
<td align="left" rowspan="1" colspan="1">China</td>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">Bladder</td>
<td align="left" rowspan="1" colspan="1">433</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">517</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.007</td>
<td align="left" rowspan="1" colspan="1"><bold>0.000</bold></td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Srivastava K<sup>38</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Gallbladder</td>
<td align="left" rowspan="1" colspan="1">195</td>
<td align="left" rowspan="1" colspan="1">32</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">232</td>
<td align="left" rowspan="1" colspan="1">24</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.051</td>
<td align="left" rowspan="1" colspan="1">0.656</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Balistreri CR<sup>31</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Prostate</td>
<td align="left" rowspan="1" colspan="1">48</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">118</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.028</td>
<td align="left" rowspan="1" colspan="1">0.747</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Rigoli L<sup>27</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2010</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">13</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">81</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.034</td>
<td align="left" rowspan="1" colspan="1">0.739</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Pandey S<sup>39</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2009</td>
<td align="left" rowspan="1" colspan="1">India</td>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">Cervical</td>
<td align="left" rowspan="1" colspan="1">127</td>
<td align="left" rowspan="1" colspan="1">21</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">133</td>
<td align="left" rowspan="1" colspan="1">16</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0.060</td>
<td align="left" rowspan="1" colspan="1">0.505</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Trejo-de la OA<sup>24</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">Mexico</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">57</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">193</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.022</td>
<td align="left" rowspan="1" colspan="1">0.746</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Santini D<sup>25</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2008</td>
<td align="left" rowspan="1" colspan="1">Italy</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">155</td>
<td align="left" rowspan="1" colspan="1">15</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">147</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.013</td>
<td align="left" rowspan="1" colspan="1">0.869</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Garza-Gonzalez E<sup>26</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2007</td>
<td align="left" rowspan="1" colspan="1">Mexico</td>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">Gastric</td>
<td align="left" rowspan="1" colspan="1">77</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">179</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.026</td>
<td align="left" rowspan="1" colspan="1">0.709</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>Boraska Jelavic T<sup>49</sup></bold></td>
<td align="left" rowspan="1" colspan="1">2006</td>
<td align="left" rowspan="1" colspan="1">Croatia</td>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">Colorectal</td>
<td align="left" rowspan="1" colspan="1">77</td>
<td align="left" rowspan="1" colspan="1">12</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">82</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0</td>
<td align="left" rowspan="1" colspan="1">0.029</td>
<td align="left" rowspan="1" colspan="1">0.783</td>
</tr>
</tbody>
</table>
</alternatives></table-wrap></sec><sec id="s3b">
<title>Meta-analysis Results</title>
<p>The main results of this meta-analysis were listed in <xref ref-type="table" rid="pone-0082858-t002">Table 2</xref> and <xref ref-type="supplementary-material" rid="pone.0082858.s002">Figure S1</xref>. For <italic>TLR2</italic> polymorphism (−196 to −174 del), the meta-analysis showed a significantly increased risk for all cancers (allele comparison: OR = 1.62, 95% CI: 1.09–2.43, <italic>P</italic>&lt;0.001 for heterogeneity test; dominant model: OR = 1.64, 95% CI: 1.04–2.60, <italic>P</italic>&lt;0.001 for heterogeneity test; recessive model: OR = 2.28, 95% CI: 1.23–4.20, <italic>P</italic>&lt;0.001 for heterogeneity test). Similarly, both of <italic>TLR4</italic> rs4986790 (allele comparison: OR = 1.17, 95% CI: 1.00–1.37, <italic>P</italic>&lt;0.001 for heterogeneity test; dominant model: OR = 1.19, 95% CI: 1.01–1.41, <italic>P</italic>&lt;0.001 for heterogeneity test) and rs4986791 (allele comparison: OR = 1.47, 95% CI: 1.21–1.78, <italic>P</italic> = 0.070 for heterogeneity test; dominant model: OR = 1.47, 95% CI: 1.20–1.80, <italic>P</italic> = 0.078 for heterogeneity test) also significantly increased the overall cancer risk.</p>
<table-wrap id="pone-0082858-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.t002</object-id><label>Table 2</label><caption>
<title>Associations between <italic>TLRs</italic> polymorphisms and overall cancer risk by races.</title>
</caption><alternatives><graphic id="pone-0082858-t002-2" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.t002" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Polymorphism</td>
<td align="left" rowspan="1" colspan="1">Ethnicities</td>
<td align="left" rowspan="1" colspan="1">Studies</td>
<td colspan="2" align="left" rowspan="1">Allele comparison</td>
<td colspan="2" align="left" rowspan="1">Dominant model</td>
<td colspan="2" align="left" rowspan="1">Recessive model</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt102">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt102">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt102">*</xref></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">−<bold>196 to</bold> −<bold>174 del</bold></td>
<td align="left" rowspan="1" colspan="1">Total</td>
<td align="left" rowspan="1" colspan="1">10</td>
<td align="left" rowspan="1" colspan="1"><bold>1.62(1.09–2.43)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>1.64(1.04–2.60)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>2.28(1.23–4.20)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1"><bold>3.29(1.14–9.51)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>3.56(1.10–11.51)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>7.29(1.75–30.37)</bold></td>
<td align="left" rowspan="1" colspan="1">0.029</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">1.04(0.71–1.52)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">0.96(0.66–1.40)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.27(0.55–2.95)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1"><bold>1.32(1.11–1.58)</bold></td>
<td align="left" rowspan="1" colspan="1">0.785</td>
<td align="left" rowspan="1" colspan="1"><bold>1.37(1.11–1.68)</bold></td>
<td align="left" rowspan="1" colspan="1">0.870</td>
<td align="left" rowspan="1" colspan="1">1.72(0.94–3.14)</td>
<td align="left" rowspan="1" colspan="1">0.751</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986790</bold></td>
<td align="left" rowspan="1" colspan="1">Total</td>
<td align="left" rowspan="1" colspan="1">27</td>
<td align="left" rowspan="1" colspan="1"><bold>1.17(1.00–1.37)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>1.19(1.01–1.41)</bold></td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">19</td>
<td align="left" rowspan="1" colspan="1">1.17(0.95–1.45)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.18(0.95–1.47)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">1.04(0.79–1.36)</td>
<td align="left" rowspan="1" colspan="1">0.770</td>
<td align="left" rowspan="1" colspan="1">1.08(0.81–1.45)</td>
<td align="left" rowspan="1" colspan="1">0.797</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">1</td>
<td align="left" rowspan="1" colspan="1">1.37(0.82–2.30)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.44(0.82–2.52)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">1.05(0.87–1.27)</td>
<td align="left" rowspan="1" colspan="1">0.348</td>
<td align="left" rowspan="1" colspan="1">1.08(0.89–1.32)</td>
<td align="left" rowspan="1" colspan="1">0.320</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986791</bold></td>
<td align="left" rowspan="1" colspan="1">Total</td>
<td align="left" rowspan="1" colspan="1">14</td>
<td align="left" rowspan="1" colspan="1"><bold>1.47(1.21–1.78)</bold></td>
<td align="left" rowspan="1" colspan="1">0.070</td>
<td align="left" rowspan="1" colspan="1"><bold>1.47(1.20–1.80)</bold></td>
<td align="left" rowspan="1" colspan="1">0.078</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Caucasian</td>
<td align="left" rowspan="1" colspan="1">7</td>
<td align="left" rowspan="1" colspan="1">1.51(0.84–2.71)</td>
<td align="left" rowspan="1" colspan="1">0.023</td>
<td align="left" rowspan="1" colspan="1">1.55(0.85–2.83)</td>
<td align="left" rowspan="1" colspan="1">0.023</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">East Asian</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1"><bold>1.72(1.14–2.62)</bold></td>
<td align="left" rowspan="1" colspan="1">0.198</td>
<td align="left" rowspan="1" colspan="1"><bold>1.77(1.12–2.77)</bold></td>
<td align="left" rowspan="1" colspan="1">0.192</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">South Asian</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1"><bold>1.58(1.16–2.16)</bold></td>
<td align="left" rowspan="1" colspan="1">0.718</td>
<td align="left" rowspan="1" colspan="1"><bold>1.55(1.11–2.17)</bold></td>
<td align="left" rowspan="1" colspan="1">0.846</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Mixed</td>
<td align="left" rowspan="1" colspan="1">2</td>
<td align="left" rowspan="1" colspan="1">0.75 (0.28–2.01)</td>
<td align="left" rowspan="1" colspan="1">0.117</td>
<td align="left" rowspan="1" colspan="1">0.75(0.28–2.02)</td>
<td align="left" rowspan="1" colspan="1">0.114</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt101"><label/><p>The results were in bold, if the <italic>P</italic>&lt;0.05.</p></fn><fn id="nt102"><label>*</label><p><italic>P</italic> values for heterogeneity test. If the result of the heterogeneity test was <italic>p</italic>&gt;0.05, ORs were pooled according to the fixed-effect model. Otherwise, the random-effect model was used.</p></fn></table-wrap-foot></table-wrap>
<p>We further performed stratification analysis by ethnicity and cancer types. The results indicated that variant genotypes of <italic>TLR2</italic> −196 to −174 del tended to be associated with overall cancer risk in Caucasians (allele comparison: OR = 3.29, 95% CI: 1.14–9.51, <italic>P</italic>&lt;0.001 for heterogeneity test; dominant model: OR = 3.56, 95% CI: 1.10–11.51, <italic>P</italic>&lt;0.001 for heterogeneity test) and South Asians (allele comparison: OR = 1.32, 95% CI: 1.11–1.58, <italic>P</italic> = 0.785 for heterogeneity test; dominant model: OR = 1.37, 95% CI: 1.11–1.68, <italic>P</italic> = 0.870 for heterogeneity test), but not in East Asians (<xref ref-type="table" rid="pone-0082858-t002">Table 2</xref>). However, the association between rs4986791 and cancer risk was significant in both South Asians (allele comparison: OR = 1.58, 95% CI: 1.16–2.16, <italic>P</italic> = 0.718 for heterogeneity test; dominant model: OR = 1.55, 95% CI: 1.11–2.17, <italic>P</italic> = 0.846 for heterogeneity test) and East Asians (allele comparison: OR = 1.72, 95% CI: 1.14–2.62, <italic>P</italic> = 0.198 for heterogeneity test; dominant model: OR = 1.77, 95% CI: 1.12–2.77, <italic>P</italic> = 0.192 for heterogeneity test), but not in Caucasians (<xref ref-type="table" rid="pone-0082858-t002">Table 2</xref>). When stratified by cancer types, significantly increased risks of <italic>TLR4</italic> rs4986790 were found in digestive cancers (allele comparison: OR = 1.79, 95% CI: 1.14–2.81, <italic>P</italic> = 0.001 for heterogeneity test; dominant model: OR = 1.76, 95% CI: 1.13–2.73, <italic>P</italic> = 0.003 for heterogeneity test) and female-specific cancers (allele comparison: OR = 1.44, 95% CI: 1.14–1.83, <italic>P</italic> = 0.641 for heterogeneity test; dominant model: OR = 1.50, 95% CI: 1.16–1.94, <italic>P</italic> = 0.537 for heterogeneity test), but not in blood cancers or male-specific cancers (<xref ref-type="table" rid="pone-0082858-t003">Table 3</xref>). However, no significant association with risk of digestive cancers was observed for <italic>TLR2</italic> −196 to −174 del and <italic>TLR4</italic> rs4986791 (<xref ref-type="table" rid="pone-0082858-t003">Table 3</xref>). We also further investigated the associations between three SNPs and gastric cancer or prostate cancer (involved in more than three studies) and found that both <italic>TLR4</italic> rs4986790 (allele comparison: OR = 2.18, 95% CI: 1.67–2.84, <italic>P</italic> = 0.068 for heterogeneity test; dominant model: OR = 2.20, 95% CI: 1.67–2.89, <italic>P</italic> = 0.104 for heterogeneity test) and rs4986791 (allele comparison: OR = 1.90, 95% CI: 1.20–3.12, <italic>P</italic> = 0.193 for heterogeneity test; dominant model: OR = 1.98, 95% CI: 1.22–3.21, <italic>P</italic> = 0.104 for heterogeneity test) were associated with a significantly increased risk of gastric cancer, but not <italic>TLR2</italic> −196 to −174 del (<xref ref-type="table" rid="pone-0082858-t004">Table 4</xref>). Furthermore, we did not observe significant association between rs4986790 and prostate cancer risk.</p>
<table-wrap id="pone-0082858-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.t003</object-id><label>Table 3</label><caption>
<title>Associations between <italic>TLRs</italic> polymorphisms and overall cancer risk by cancer types.</title>
</caption><alternatives><graphic id="pone-0082858-t003-3" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.t003" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Polymorphism</td>
<td align="left" rowspan="1" colspan="1">Cancer type</td>
<td align="left" rowspan="1" colspan="1">Studies</td>
<td colspan="2" align="left" rowspan="1">Allele comparison</td>
<td colspan="2" align="left" rowspan="1">Dominant model</td>
<td colspan="2" align="left" rowspan="1">Recessive model</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt104">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt104">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt104">*</xref></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">−<bold>196 to</bold> −<bold>174 del</bold></td>
<td align="left" rowspan="1" colspan="1">Digestive</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">1.32(0.97–1.79)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.29(0.92–1.80)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.74(0.91–3.34)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Others</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">2.19(0.82–5.82)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.32(0.80–6.77)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">3.93(0.89–17.47)</td>
<td align="left" rowspan="1" colspan="1">0.002</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986790</bold></td>
<td align="left" rowspan="1" colspan="1">Digestive</td>
<td align="left" rowspan="1" colspan="1">9</td>
<td align="left" rowspan="1" colspan="1"><bold>1.79(1.14–2.81)</bold></td>
<td align="left" rowspan="1" colspan="1">0.001</td>
<td align="left" rowspan="1" colspan="1"><bold>1.76(1.13–2.73)</bold></td>
<td align="left" rowspan="1" colspan="1">0.003</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Blood</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1">0.95(0.83–1.10)</td>
<td align="left" rowspan="1" colspan="1">0.170</td>
<td align="left" rowspan="1" colspan="1">0.95(0.83–1.11)</td>
<td align="left" rowspan="1" colspan="1">0.140</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Female-specific</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1"><bold>1.44(1.14–1.83)</bold></td>
<td align="left" rowspan="1" colspan="1">0.641</td>
<td align="left" rowspan="1" colspan="1"><bold>1.50(1.16–1.94)</bold></td>
<td align="left" rowspan="1" colspan="1">0.537</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Male-specific</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.95(0.80–1.13)</td>
<td align="left" rowspan="1" colspan="1">0.068</td>
<td align="left" rowspan="1" colspan="1">0.99(0.82–1.18)</td>
<td align="left" rowspan="1" colspan="1">0.062</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">other</td>
<td align="left" rowspan="1" colspan="1">3</td>
<td align="left" rowspan="1" colspan="1">1.11(0.87–1.43)</td>
<td align="left" rowspan="1" colspan="1">0.535</td>
<td align="left" rowspan="1" colspan="1">1.16(0.89–1.52)</td>
<td align="left" rowspan="1" colspan="1">0.666</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986791</bold></td>
<td align="left" rowspan="1" colspan="1">Digestive</td>
<td align="left" rowspan="1" colspan="1">8</td>
<td align="left" rowspan="1" colspan="1">1.58(0.93–2.69)</td>
<td align="left" rowspan="1" colspan="1">0.014</td>
<td align="left" rowspan="1" colspan="1">1.60(0.94–2.74)</td>
<td align="left" rowspan="1" colspan="1">0.017</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Others</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"><bold>1.47(1.13–1.92)</bold></td>
<td align="left" rowspan="1" colspan="1">0.607</td>
<td align="left" rowspan="1" colspan="1"><bold>1.47(1.11–1.96)</bold></td>
<td align="left" rowspan="1" colspan="1">0.589</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt103"><label/><p>The results were in bold, if the <italic>P</italic>&lt;0.05.</p></fn><fn id="nt104"><label>*</label><p><italic>P</italic> values for heterogeneity test. If the result of the heterogeneity test was <italic>p</italic>&gt;0.05, ORs were pooled according to the fixed-effect model. Otherwise, the random-effect model was used.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0082858-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.t004</object-id><label>Table 4</label><caption>
<title>Main result of pooled odds ratios (ORs) in gastric and prostate cancer.</title>
</caption><alternatives><graphic id="pone-0082858-t004-4" position="float" mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.t004" xlink:type="simple"/>
<table><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup>
<thead>
<tr>
<td align="left" rowspan="1" colspan="1">Polymorphism</td>
<td align="left" rowspan="1" colspan="1">Cancer type</td>
<td align="left" rowspan="1" colspan="1">Studies</td>
<td colspan="2" align="left" rowspan="1">Allele comparison</td>
<td colspan="2" align="left" rowspan="1">Dominant model</td>
<td colspan="2" align="left" rowspan="1">Recessive model</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt106">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt106">*</xref></td>
<td align="left" rowspan="1" colspan="1">OR(95% CI)</td>
<td align="left" rowspan="1" colspan="1"><italic>p</italic><xref ref-type="table-fn" rid="nt106">*</xref></td>
</tr>
</thead>
<tbody>
<tr>
<td align="left" rowspan="1" colspan="1">−<bold>196 to</bold> −<bold>174 del</bold></td>
<td align="left" rowspan="1" colspan="1">Gastric cancer</td>
<td align="left" rowspan="1" colspan="1">4</td>
<td align="left" rowspan="1" colspan="1">1.27(0.83–1.95)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.21(0.75–1.94)</td>
<td align="left" rowspan="1" colspan="1">&lt;0.001</td>
<td align="left" rowspan="1" colspan="1">1.58(0.70–3.59) &lt;0.001</td>
<td align="left" rowspan="1" colspan="1"/>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986790</bold></td>
<td align="left" rowspan="1" colspan="1">Gastric cancer</td>
<td align="left" rowspan="1" colspan="1">6</td>
<td align="left" rowspan="1" colspan="1"><bold>2.18(1.67–2.84)</bold></td>
<td align="left" rowspan="1" colspan="1">0.068</td>
<td align="left" rowspan="1" colspan="1"><bold>2.20(1.67–2.89)</bold></td>
<td align="left" rowspan="1" colspan="1">0.104</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"/>
<td align="left" rowspan="1" colspan="1">Prostate cancer</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1">0.95(0.80–1.13)</td>
<td align="left" rowspan="1" colspan="1">0.068</td>
<td align="left" rowspan="1" colspan="1">0.99(0.82–1.18)</td>
<td align="left" rowspan="1" colspan="1">0.062</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
<tr>
<td align="left" rowspan="1" colspan="1"><bold>rs4986791</bold></td>
<td align="left" rowspan="1" colspan="1">Gastric cancer</td>
<td align="left" rowspan="1" colspan="1">5</td>
<td align="left" rowspan="1" colspan="1"><bold>1.93(1.20–3.12)</bold></td>
<td align="left" rowspan="1" colspan="1">0.193</td>
<td align="left" rowspan="1" colspan="1"><bold>1.98(1.22–3.21)</bold></td>
<td align="left" rowspan="1" colspan="1">0.177</td>
<td align="left" rowspan="1" colspan="1">–</td>
<td align="left" rowspan="1" colspan="1">–</td>
</tr>
</tbody>
</table>
</alternatives><table-wrap-foot><fn id="nt105"><label/><p>The results were in bold, if the <italic>P</italic>&lt;0.05.</p></fn><fn id="nt106"><label>*</label><p><italic>P</italic> values for heterogeneity test. If the result of the heterogeneity test was <italic>p</italic>&gt;0.05, ORs were pooled according to the fixed-effect model. Otherwise, the random-effect model was used.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c">
<title>Test of Heterogeneity</title>
<p>A meta-regression was conducted to explore the possible source of heterogeneity for −196 to −174 del and rs4986790 because both of <italic>P</italic> values for heterogeneity test were less than 0.05 in the comparisons. We identified that MAFs of −196 to −174 del and rs4986790 were significant sources of heterogeneity (<italic>P</italic> = 0.008 for −196 to −174 del, <italic>P</italic> = 0.039 for rs4986790, respectively). We also found that ethnicity was a significant source of heterogeneity for −196 to −174 (<italic>P</italic> = 0.036). However, genotyping methods, tumor types, sample size, and source of controls could not substantially influence the initial heterogeneity.</p>
</sec><sec id="s3d">
<title>Sensitivity Analyses and Publication Bias</title>
<p>The leave-one-out sensitivity analysis indicated that no single study changed the pooled ORs qualitatively (data not shown). Furthermore, we also conducted a sensitivity analysis on the <italic>TLR2</italic> and <italic>TLR4</italic> polymorphism and risk of cancer by excluding all four studies departure from HWE among controls <xref ref-type="bibr" rid="pone.0082858-Shen1">[20]</xref>, <xref ref-type="bibr" rid="pone.0082858-Chen2">[35]</xref>, <xref ref-type="bibr" rid="pone.0082858-Srivastava1">[40]</xref>, <xref ref-type="bibr" rid="pone.0082858-Yang1">[42]</xref> and their exclusion did not substantially affect the results of the meta-analysis (dominant model: OR = 1.68, 95% CI: 1.00–2.81 for −196 to −174del; dominant model: OR = 1.20, 95% CI: 1.00–1.44 for rs4986790; dominant model: OR = 1.49, 95% CI: 1.21–1.83 for rs4986791).</p>
<p>The inverted funnel plots (<xref ref-type="fig" rid="pone-0082858-g002">Figure 2</xref>) and Begg’s test were performed to assess the publication bias, and the results did not suggest any obvious evidence of asymmetry for <italic>TLR2</italic> and <italic>TLR4</italic> polymorphisms (<italic>P</italic> = 0.152 for −196 to −174 del; <italic>P</italic> = 0.505 for rs4986790; <italic>P</italic> = 0.324 for rs4986791, respectively).</p>
<fig id="pone-0082858-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0082858.g002</object-id><label>Figure 2</label><caption>
<title>Begg’s funnel plot for publication bias test.</title>
<p>Each point represents a separate study for the indicated association. s.e., standardized effect.</p>
</caption><graphic mimetype="image" xlink:href="info:doi/10.1371/journal.pone.0082858.g002" position="float" xlink:type="simple"/></fig></sec></sec><sec id="s4">
<title>Discussion</title>
<p>In this meta-analysis of 34 independent publications, we found that three genetic variants of <italic>TLRs</italic> (<italic>TLR2</italic> −196 to −174 del, <italic>TLR4</italic> rs4986790 and rs4986791) were significantly associated with an increased risk of overall cancers. Furthermore, the stratification analysis showed that the risk effect of polymorphisms was more prominent in subjects with some special races or cancer types. All these findings suggested that polymorphisms of <italic>TLR2</italic> and <italic>TLR4</italic> might contribute to risk of human cancer.</p>
<p>The −196 to −174 del polymorphism in <italic>TLR2</italic> located on chromosome 4 causes a 22-bp nucleotide deletion and it has been recently proposed to reflect differential trans-activation of <italic>TLR2</italic> promoter constructs and expression levels of <italic>TLR2</italic> <xref ref-type="bibr" rid="pone.0082858-Nischalke1">[38]</xref>. However, population studies showed that <italic>TLR2</italic> −196 to −174 del polymorphism might play conflicting roles for the risk of different types of cancer. For example, it was reported that the <italic>TLR2</italic> −196 to −174 del polymorphism was associated with risk of several cancers, such as cervical cancer, gastric cancer, breast cancer and hepatocellular cancer <xref ref-type="bibr" rid="pone.0082858-Theodoropoulos1">[21]</xref>, <xref ref-type="bibr" rid="pone.0082858-deOliveira1">[23]</xref>, <xref ref-type="bibr" rid="pone.0082858-Zeng1">[24]</xref>, <xref ref-type="bibr" rid="pone.0082858-Nischalke1">[38]</xref>, <xref ref-type="bibr" rid="pone.0082858-Pandey1">[41]</xref>, but not associated with other cancers including bladder, prostate cancer and gallbladder cancer <xref ref-type="bibr" rid="pone.0082858-Singh1">[19]</xref>, <xref ref-type="bibr" rid="pone.0082858-Mandal1">[32]</xref>, <xref ref-type="bibr" rid="pone.0082858-Srivastava1">[40]</xref>. And even the same kind of cancer, the results were inconsistent <xref ref-type="bibr" rid="pone.0082858-deOliveira1">[23]</xref>, <xref ref-type="bibr" rid="pone.0082858-Hishida1">[25]</xref>. To comprehensively investigate the effect of this polymorphism on the risk of overall cancers, we conducted this meta-analysis and found that <italic>TLR2</italic> −196 to −174 del polymorphism significantly increased risk of cancers, supporting the hypothesis that this SNP plays a role in changed expression of <italic>TLR2</italic> and cancer development.</p>
<p>The <italic>TLR4</italic> gene is mapped on chromosome 9 and consists of three exons. In exon 3, two non-synonymous SNPs (+896A/G rs4986790 and +1196C/T rs4986791) induces the substitution of amino acids Asp299Gly and Thr399Ile, respectively. The substitution of Asp299Gly disrupts the normal structure of the extracellular region of the <italic>TLR4</italic>, which may cause decreased ligand recognition or protein interaction and decreased responsiveness to lipopolysaccharide <xref ref-type="bibr" rid="pone.0082858-Arbour1">[57]</xref>. Consequently, such change can affect the transport of <italic>TLR4</italic> to the cell membrane and lead to an exaggerated inflammatory response with severe tissue destruction. The results of previous studies regarding the association between these two SNPs and cancer risk were inconsistent. These pooled analysis did not find any significant association between the two SNPs and risk of prostate cancer <xref ref-type="bibr" rid="pone.0082858-Lindstrom1">[58]</xref> or gastric cancer <xref ref-type="bibr" rid="pone.0082858-CastanoRodriguez1">[59]</xref>. However, a recent meta-analysis of 22 publications on six selected SNPs (rs1927914, rs4986790, rs4986791, rs11536889, rs1927911 and rs2149356) in <italic>TLR4</italic> and cancer risk reported that <italic>TLR4</italic> rs4986790 and rs4986791 were significantly associated with increased risk of overall cancer and significantly elevated risk of gastric cancer was observed for rs4986790 in a stratification study <xref ref-type="bibr" rid="pone.0082858-Zhang1">[60]</xref>. Our meta-analysis including more studies (27 studies for rs4986790 and 14 studies for rs4986791) and more cancer types provided additional evidence that these two SNPs may play a role in the development of cancer. In the stratification analysis by cancer types, we found that the effect of rs4986790 on cancer risk was more evident in female-specific cancers and digestive cancers, especially for gastric cancer. Similarly, the risk effect of rs4986791 was also prominent in gastric cancer. Studies have shown that H.pylori activates <italic>TLR4</italic> expression in gastric epithelial cells and TLR4 can serve as a receptor for H.pylori binding <xref ref-type="bibr" rid="pone.0082858-Su1">[61]</xref>, <xref ref-type="bibr" rid="pone.0082858-Wroblewski1">[62]</xref>. Thus, potentially functional polymorphisms of <italic>TLR4</italic> may affect the function of <italic>TLR4</italic> and contribute to H. pylori-associated carcinogenesis. An important reason for the different findings by previously performed studies may be the insufficient study power to detect modest effects of polymorphisms.</p>
<p>In term of stratified analyses by races, our findings indicated that <italic>TLR2</italic> −196 to −174 del had an significant association with cancer risk in Caucasians and South Asians, but not in East Asians. However, the association between <italic>TLR4</italic> rs4986791 and cancer risk was significant in both South Asians and East Asians, but not in Caucasians. These differences may be induced by different genetic backgrounds and environmental exposures, as indicated by the difference of minor allele frequency in controls among the two populations (<xref ref-type="table" rid="pone-0082858-t001">Table 1</xref>). For example, the MAF of <italic>TLR2</italic> −196 to −174 del in Caucasian controls varied from 0.05 to 0.15, but that in Asians was from 0.12 to 0.38. Allele frequency might reflect the natural selection pressures or a balance by other related functional genetic variants and/or environmental exposures. We also searched some public databases, such as Hapmap (<ext-link ext-link-type="uri" xlink:href="http://hapmap.ncbi.nlm.nih.gov/" xlink:type="simple">http://hapmap.ncbi.nlm.nih.gov/</ext-link>) and SNPinfo (<ext-link ext-link-type="uri" xlink:href="http://snpinfo.niehs.nih.gov/" xlink:type="simple">http://snpinfo.niehs.nih.gov/</ext-link>), and found that rs4986790 was in high linkage disequilibrium (LD) with rs4986791 in Caucasians (r<sup>2</sup> = 1), but not data was available in Asians because of low allele frequency of these two SNPs. In our analysis, the associations of rs4986790 and rs4986791 with cancer risk were consistent in Caucasians, but inconsistent in Asians. These findings further indicate that the effect of genetic variants on cancer risk may be different between multiple ethnic groups. Some limitations and potential bias should be addressed. First, the subgroups may have a relatively lower power based on a small number of studies. Second, a more precise analysis should be conducted, if individual data were available, allowing for the adjustment by some co-variants such as age, gender and other environmental factors. However, these information were unavailable from most of studies. Third, the controls in the included studies were recruited from different ways and not uniformly defined, which may have induced some bias for the meta-analysis. Last, the gene-gene interaction is important for the development of complex diseases including cancer because single genetic variation may only have a modest effect <xref ref-type="bibr" rid="pone.0082858-Liu1">[63]</xref>, <xref ref-type="bibr" rid="pone.0082858-Zhong1">[64]</xref>. However, the original genotyping data of each publication was unavailable and we could not carry out gene-gene interaction analysis in this study.</p>
<p>In conclusion, this meta-analysis provided statistical evidence that the <italic>TLR2</italic> and <italic>TLR4</italic> polymorphisms were associated with cancer risk, particularly for gastric cancer. However, due to the limitations of original studies included in the meta-analyses, well-designed prospective studies with larger samples are needed to confirm these findings.</p>
</sec><sec id="s5">
<title>Supporting Information</title>
<supplementary-material id="pone.0082858.s001" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0082858.s001" position="float" xlink:type="simple"><label>Checklist S1</label><caption>
<p>(DOC)</p>
</caption></supplementary-material><supplementary-material id="pone.0082858.s002" mimetype="application/msword" xlink:href="info:doi/10.1371/journal.pone.0082858.s002" position="float" xlink:type="simple"><label>Figure S1</label><caption>
<p>(DOC)</p>
</caption></supplementary-material></sec></body>
<back><ref-list>
<title>References</title>
<ref id="pone.0082858-Kawai1"><label>1</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kawai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Akira</surname><given-names>S</given-names></name> (<year>2010</year>) <article-title>The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors</article-title>. <source>Nat Immunol</source> <volume>11</volume>: <fpage>373</fpage>–<lpage>384</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Iwasaki1"><label>2</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Iwasaki</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Medzhitov</surname><given-names>R</given-names></name> (<year>2010</year>) <article-title>Regulation of adaptive immunity by the innate immune system</article-title>. <source>Science</source> <volume>327</volume>: <fpage>291</fpage>–<lpage>295</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Wang1"><label>3</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>RF</given-names></name>, <name name-style="western"><surname>Miyahara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>HY</given-names></name> (<year>2008</year>) <article-title>Toll-like receptors and immune regulation: implications for cancer therapy</article-title>. <source>Oncogene</source> <volume>27</volume>: <fpage>181</fpage>–<lpage>189</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Basith1"><label>4</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Basith</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Manavalan</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Yoo</surname><given-names>TH</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>SG</given-names></name>, <name name-style="western"><surname>Choi</surname><given-names>S</given-names></name> (<year>2012</year>) <article-title>Roles of toll-like receptors in cancer: a double-edged sword for defense and offense</article-title>. <source>Arch Pharm Res</source> <volume>35</volume>: <fpage>1297</fpage>–<lpage>1316</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Takeda1"><label>5</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takeda</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kaisho</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Akira</surname><given-names>S</given-names></name> (<year>2003</year>) <article-title>Toll-like receptors</article-title>. <source>Annu Rev Immunol</source> <volume>21</volume>: <fpage>335</fpage>–<lpage>376</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Aderem1"><label>6</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Aderem</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ulevitch</surname><given-names>RJ</given-names></name> (<year>2000</year>) <article-title>Toll-like receptors in the induction of the innate immune response</article-title>. <source>Nature</source> <volume>406</volume>: <fpage>782</fpage>–<lpage>787</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Drexler1"><label>7</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Drexler</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Foxwell</surname><given-names>BM</given-names></name> (<year>2010</year>) <article-title>The role of toll-like receptors in chronic inflammation</article-title>. <source>Int J Biochem Cell Biol</source> <volume>42</volume>: <fpage>506</fpage>–<lpage>518</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Menendez1"><label>8</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Menendez</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Shatz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Azzam</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Garantziotis</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fessler</surname><given-names>MB</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>The Toll-like receptor gene family is integrated into human DNA damage and p53 networks</article-title>. <source>PLoS Genet</source> <volume>7</volume>: <fpage>e1001360</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Harberts1"><label>9</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Harberts</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Gaspari</surname><given-names>AA</given-names></name> (<year>2013</year>) <article-title>TLR signaling and DNA repair: are they associated?</article-title> <source>J Invest Dermatol</source> <volume>133</volume>: <fpage>296</fpage>–<lpage>302</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Kagan1"><label>10</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Kagan</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Horng</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Akira</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>TRAM couples endocytosis of Toll-like receptor 4 to the induction of interferon-beta</article-title>. <source>Nat Immunol</source> <volume>9</volume>: <fpage>361</fpage>–<lpage>368</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Sabroe1"><label>11</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sabroe</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Dower</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Whyte</surname><given-names>MK</given-names></name> (<year>2005</year>) <article-title>The role of Toll-like receptors in the regulation of neutrophil migration, activation, and apoptosis</article-title>. <source>Clin Infect Dis</source> <volume>41</volume> Suppl 7<fpage>S421</fpage>–<lpage>426</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Takeuchi1"><label>12</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Takeuchi</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Hoshino</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kawai</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Sanjo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Takada</surname><given-names>H</given-names></name>, <etal>et al</etal>. (<year>1999</year>) <article-title>Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components</article-title>. <source>Immunity</source> <volume>11</volume>: <fpage>443</fpage>–<lpage>451</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Huang1"><label>13</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Huang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shen</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>H</given-names></name>, <name name-style="western"><surname>He</surname><given-names>KL</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling</article-title>. <source>Cancer Res</source> <volume>67</volume>: <fpage>4346</fpage>–<lpage>4352</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Chen1"><label>14</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Alvero</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Silasi</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Steffensen</surname><given-names>KD</given-names></name>, <name name-style="western"><surname>Mor</surname><given-names>G</given-names></name> (<year>2008</year>) <article-title>Cancers take their Toll–the function and regulation of Toll-like receptors in cancer cells</article-title>. <source>Oncogene</source> <volume>27</volume>: <fpage>225</fpage>–<lpage>233</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-He1"><label>15</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>He</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Chen</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance</article-title>. <source>Mol Immunol</source> <volume>44</volume>: <fpage>2850</fpage>–<lpage>2859</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Wang2"><label>16</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>JH</given-names></name>, <name name-style="western"><surname>Manning</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>QD</given-names></name>, <name name-style="western"><surname>Blankson</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bouchier-Hayes</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2003</year>) <article-title>Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism</article-title>. <source>J Immunol</source> <volume>170</volume>: <fpage>795</fpage>–<lpage>804</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Ahmed1"><label>17</label>
<mixed-citation publication-type="other" xlink:type="simple">Ahmed A, Wang JH, Redmond HP (2012) Silencing of TLR4 Increases Tumor Progression and Lung Metastasis in a Murine Model of Breast Cancer. Ann Surg Oncol.</mixed-citation>
</ref>
<ref id="pone.0082858-Ferwerda1"><label>18</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferwerda</surname><given-names>B</given-names></name>, <name name-style="western"><surname>McCall</surname><given-names>MB</given-names></name>, <name name-style="western"><surname>Verheijen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Kullberg</surname><given-names>BJ</given-names></name>, <name name-style="western"><surname>van der Ven</surname><given-names>AJ</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Functional consequences of toll-like receptor 4 polymorphisms</article-title>. <source>Mol Med</source> <volume>14</volume>: <fpage>346</fpage>–<lpage>352</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Singh1"><label>19</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Singh</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kapoor</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Mittal</surname><given-names>RD</given-names></name> (<year>2013</year>) <article-title>Single-nucleotide polymorphisms in genes encoding toll-like receptor −2, −3, −4, and −9 in a case-control study with bladder cancer susceptibility in a North Indian population</article-title>. <source>Arch Med Res</source> <volume>44</volume>: <fpage>54</fpage>–<lpage>61</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Shen1"><label>20</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Shen</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>A</given-names></name> (<year>2013</year>) <article-title>Toll-like receptor 4 gene polymorphisms and susceptibility to bladder cancer</article-title>. <source>Pathol Oncol Res</source> <volume>19</volume>: <fpage>275</fpage>–<lpage>280</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Theodoropoulos1"><label>21</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Theodoropoulos</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Saridakis</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Karantanos</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Michalopoulos</surname><given-names>NV</given-names></name>, <name name-style="western"><surname>Zagouri</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development</article-title>. <source>Breast</source> <volume>21</volume>: <fpage>534</fpage>–<lpage>538</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Etokebe1"><label>22</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Etokebe</surname><given-names>GE</given-names></name>, <name name-style="western"><surname>Knezevic</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Petricevic</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Pavelic</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Vrbanec</surname><given-names>D</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Single-nucleotide polymorphisms in genes encoding toll-like receptor −2, −3, −4, and −9 in case-control study with breast cancer</article-title>. <source>Genet Test Mol Biomarkers</source> <volume>13</volume>: <fpage>729</fpage>–<lpage>734</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-deOliveira1"><label>23</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>de Oliveira</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>AE</given-names></name> (<year>2012</year>) <article-title>Polymorphisms of the TLR2 and TLR4 genes are associated with risk of gastric cancer in a Brazilian population</article-title>. <source>World J Gastroenterol</source> <volume>18</volume>: <fpage>1235</fpage>–<lpage>1242</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Zeng1"><label>24</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zeng</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Pan</surname><given-names>KF</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>JL</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Genetic variants of toll-like receptor 2 and 5, helicobacter pylori infection, and risk of gastric cancer and its precursors in a chinese population</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>20</volume>: <fpage>2594</fpage>–<lpage>2602</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Hishida1"><label>25</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hishida</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Matsuo</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Naito</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Wakai</surname><given-names>K</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>No associations of Toll-like receptor 2 (TLR2) −196 to −174del polymorphism with the risk of Helicobacter pylori seropositivity, gastric atrophy, and gastric cancer in Japanese</article-title>. <source>Gastric Cancer</source> <volume>13</volume>: <fpage>251</fpage>–<lpage>257</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Trejodela1"><label>26</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Trejo-de la</surname><given-names>OA</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Perez-Rodriguez</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Camorlinga-Ponce</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Luna</surname><given-names>LF</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>TLR4 single-nucleotide polymorphisms alter mucosal cytokine and chemokine patterns in Mexican patients with Helicobacter pylori-associated gastroduodenal diseases</article-title>. <source>Clin Immunol</source> <volume>129</volume>: <fpage>333</fpage>–<lpage>340</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Santini1"><label>27</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Santini</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Angeletti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Ruzzo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Dicuonzo</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Galluzzo</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer of intestinal and diffuse histotypes</article-title>. <source>Clin Exp Immunol</source> <volume>154</volume>: <fpage>360</fpage>–<lpage>364</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-GarzaGonzalez1"><label>28</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Garza-Gonzalez</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Bosques-Padilla</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Mendoza-Ibarra</surname><given-names>SI</given-names></name>, <name name-style="western"><surname>Flores-Gutierrez</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Maldonado-Garza</surname><given-names>HJ</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Assessment of the toll-like receptor 4 Asp299Gly, Thr399Ile and interleukin-8–251 polymorphisms in the risk for the development of distal gastric cancer</article-title>. <source>BMC Cancer</source> <volume>7</volume>: <fpage>70</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Rigoli1"><label>29</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Rigoli</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Di Bella</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Fedele</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Procopio</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Amorini</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>TLR4 and NOD2/CARD15 genetic polymorphisms and their possible role in gastric carcinogenesis</article-title>. <source>Anticancer Res</source> <volume>30</volume>: <fpage>513</fpage>–<lpage>517</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Tahara1"><label>30</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tahara</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Arisawa</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Shibata</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nakamura</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>Toll-like receptor 2–196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer</article-title>. <source>Cancer Sci</source> <volume>98</volume>: <fpage>1790</fpage>–<lpage>1794</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Hold1"><label>31</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hold</surname><given-names>GL</given-names></name>, <name name-style="western"><surname>Rabkin</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Chow</surname><given-names>WH</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Gammon</surname><given-names>MD</given-names></name>, <etal>et al</etal>. (<year>2007</year>) <article-title>A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors</article-title>. <source>Gastroenterology</source> <volume>132</volume>: <fpage>905</fpage>–<lpage>912</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Mandal1"><label>32</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mandal</surname><given-names>RK</given-names></name>, <name name-style="western"><surname>George</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Mittal</surname><given-names>RD</given-names></name> (<year>2012</year>) <article-title>Association of Toll-like receptor (TLR) 2, 3 and 9 genes polymorphism with prostate cancer risk in North Indian population</article-title>. <source>Mol Biol Rep</source> <volume>39</volume>: <fpage>7263</fpage>–<lpage>7269</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Balistreri1"><label>33</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Balistreri</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Caruso</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Carruba</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Miceli</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Campisi</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>A pilot study on prostate cancer risk and pro-inflammatory genotypes: pathophysiology and therapeutic implications</article-title>. <source>Curr Pharm Des</source> <volume>16</volume>: <fpage>718</fpage>–<lpage>724</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Wang3"><label>34</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wang</surname><given-names>MH</given-names></name>, <name name-style="western"><surname>Helzlsouer</surname><given-names>KJ</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Hoffman-Bolton</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Clipp</surname><given-names>SL</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Association of IL10 and other immune response- and obesity-related genes with prostate cancer in CLUE II</article-title>. <source>Prostate</source> <volume>69</volume>: <fpage>874</fpage>–<lpage>885</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Chen2"><label>35</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Chen</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Giovannucci</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Lazarus</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Kraft</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Ketkar</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer</article-title>. <source>Cancer Res</source> <volume>65</volume>: <fpage>11771</fpage>–<lpage>11778</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Zheng1"><label>36</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zheng</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Augustsson-Balter</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Chang</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Hedelin</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>L</given-names></name>, <etal>et al</etal>. (<year>2004</year>) <article-title>Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the CAncer Prostate in Sweden Study</article-title>. <source>Cancer Res</source> <volume>64</volume>: <fpage>2918</fpage>–<lpage>2922</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Cheng1"><label>37</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Cheng</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Plummer</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>Casey</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Witte</surname><given-names>JS</given-names></name> (<year>2007</year>) <article-title>Toll-like receptor 4 genetic variation and advanced prostate cancer risk</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>16</volume>: <fpage>352</fpage>–<lpage>355</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Nischalke1"><label>38</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nischalke</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Coenen</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Berger</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Aldenhoff</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Muller</surname><given-names>T</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>The toll-like receptor 2 (TLR2) −196 to −174 del/ins polymorphism affects viral loads and susceptibility to hepatocellular carcinoma in chronic hepatitis C. Int J Cancer</article-title>. <volume>130</volume>: <fpage>1470</fpage>–<lpage>1475</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Agundez1"><label>39</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Agundez</surname><given-names>JA</given-names></name>, <name name-style="western"><surname>Garcia-Martin</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Devesa</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Carballo</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Martinez</surname><given-names>C</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Polymorphism of the TLR4 gene reduces the risk of hepatitis C virus-induced hepatocellular carcinoma</article-title>. <source>Oncology</source> <volume>82</volume>: <fpage>35</fpage>–<lpage>40</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Srivastava1"><label>40</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Srivastava</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kumar</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Mittal</surname><given-names>B</given-names></name> (<year>2010</year>) <article-title>Significant association between toll-like receptor gene polymorphisms and gallbladder cancer</article-title>. <source>Liver Int</source> <volume>30</volume>: <fpage>1067</fpage>–<lpage>1072</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Pandey1"><label>41</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Pandey</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Mittal</surname><given-names>RD</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Srivastava</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Singh</surname><given-names>S</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>Impact of Toll-like receptors [TLR] 2 (−196 to −174 del) and TLR 4 (Asp299Gly, Thr399Ile) in cervical cancer susceptibility in North Indian women</article-title>. <source>Gynecol Oncol</source> <volume>114</volume>: <fpage>501</fpage>–<lpage>505</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Yang1"><label>42</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Yang</surname><given-names>ZH</given-names></name>, <name name-style="western"><surname>Dai</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Gu</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>QX</given-names></name>, <name name-style="western"><surname>Gong</surname><given-names>L</given-names></name> (<year>2012</year>) <article-title>Cytokine and chemokine modification by Toll-like receptor polymorphisms is associated with nasopharyngeal carcinoma</article-title>. <source>Cancer Sci</source> <volume>103</volume>: <fpage>653</fpage>–<lpage>658</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Miedema1"><label>43</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Miedema</surname><given-names>KG</given-names></name>, <name name-style="western"><surname>Tissing</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Te Poele</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Kamps</surname><given-names>WA</given-names></name>, <name name-style="western"><surname>Alizadeh</surname><given-names>BZ</given-names></name>, <etal>et al</etal>. (<year>2012</year>) <article-title>Polymorphisms in the TLR6 gene associated with the inverse association between childhood acute lymphoblastic leukemia and atopic disease</article-title>. <source>Leukemia</source> <volume>26</volume>: <fpage>1203</fpage>–<lpage>1210</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Gast1"><label>44</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Gast</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Bermejo</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Claus</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Brandt</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Weires</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Association of inherited variation in Toll-like receptor genes with malignant melanoma susceptibility and survival</article-title>. <source>PLoS One</source> <volume>6</volume>: <fpage>e24370</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Ashton1"><label>45</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ashton</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Proietto</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Otton</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Symonds</surname><given-names>I</given-names></name>, <name name-style="western"><surname>McEvoy</surname><given-names>M</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Toll-like receptor (TLR) and nucleosome-binding oligomerization domain (NOD) gene polymorphisms and endometrial cancer risk</article-title>. <source>BMC Cancer</source> <volume>10</volume>: <fpage>382</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Purdue1"><label>46</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Purdue</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Lan</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Kricker</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Menashe</surname><given-names>I</given-names></name>, <etal>et al</etal>. (<year>2009</year>) <article-title>A pooled investigation of Toll-like receptor gene variants and risk of non-Hodgkin lymphoma</article-title>. <source>Carcinogenesis</source> <volume>30</volume>: <fpage>275</fpage>–<lpage>281</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Nieters1"><label>47</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Nieters</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Beckmann</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Deeg</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>N</given-names></name> (<year>2006</year>) <article-title>Gene polymorphisms in Toll-like receptors, interleukin-10, and interleukin-10 receptor alpha and lymphoma risk</article-title>. <source>Genes Immun</source> <volume>7</volume>: <fpage>615</fpage>–<lpage>624</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-TureOzdemir1"><label>48</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ture-Ozdemir</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gazouli</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tzivras</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Panagos</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Bovaretos</surname><given-names>N</given-names></name>, <etal>et al</etal>. (<year>2008</year>) <article-title>Association of polymorphisms of NOD2, TLR4 and CD14 genes with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma</article-title>. <source>Anticancer Res</source> <volume>28</volume>: <fpage>3697</fpage>–<lpage>3700</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Forrest1"><label>49</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Forrest</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Skibola</surname><given-names>CF</given-names></name>, <name name-style="western"><surname>Lightfoot</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Bracci</surname><given-names>PM</given-names></name>, <name name-style="western"><surname>Willett</surname><given-names>EV</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Polymorphisms in innate immunity genes and risk of non-Hodgkin lymphoma</article-title>. <source>Br J Haematol</source> <volume>134</volume>: <fpage>180</fpage>–<lpage>183</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Hellmig1"><label>50</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Hellmig</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Fischbach</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Goebeler-Kolve</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Folsch</surname><given-names>UR</given-names></name>, <name name-style="western"><surname>Hampe</surname><given-names>J</given-names></name>, <etal>et al</etal>. (<year>2005</year>) <article-title>Association study of a functional Toll-like receptor 4 polymorphism with susceptibility to gastric mucosa-associated lymphoid tissue lymphoma</article-title>. <source>Leuk Lymphoma</source> <volume>46</volume>: <fpage>869</fpage>–<lpage>872</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-BoraskaJelavic1"><label>51</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boraska Jelavic</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Barisic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Drmic Hofman</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Boraska</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Vrdoljak</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer</article-title>. <source>Clin Genet</source> <volume>70</volume>: <fpage>156</fpage>–<lpage>160</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Landi1"><label>52</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Landi</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gemignani</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Bottari</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Gioia-Patricola</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Guino</surname><given-names>E</given-names></name>, <etal>et al</etal>. (<year>2006</year>) <article-title>Polymorphisms within inflammatory genes and colorectal cancer</article-title>. <source>J Negat Results Biomed</source> <volume>5</volume>: <fpage>15</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Lau1"><label>53</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lau</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Schmid</surname><given-names>CH</given-names></name> (<year>1997</year>) <article-title>Quantitative synthesis in systematic reviews</article-title>. <source>Ann Intern Med</source> <volume>127</volume>: <fpage>820</fpage>–<lpage>826</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Mantel1"><label>54</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Mantel</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Haenszel</surname><given-names>W</given-names></name> (<year>1959</year>) <article-title>Statistical aspects of the analysis of data from retrospective studies of disease</article-title>. <source>J Natl Cancer Inst</source> <volume>22</volume>: <fpage>719</fpage>–<lpage>748</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-DerSimonian1"><label>55</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>DerSimonian</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Laird</surname><given-names>N</given-names></name> (<year>1986</year>) <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source> <volume>7</volume>: <fpage>177</fpage>–<lpage>188</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Begg1"><label>56</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Begg</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Mazumdar</surname><given-names>M</given-names></name> (<year>1994</year>) <article-title>Operating characteristics of a rank correlation test for publication bias</article-title>. <source>Biometrics</source> <volume>50</volume>: <fpage>1088</fpage>–<lpage>1101</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Arbour1"><label>57</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Arbour</surname><given-names>NC</given-names></name>, <name name-style="western"><surname>Lorenz</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Schutte</surname><given-names>BC</given-names></name>, <name name-style="western"><surname>Zabner</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kline</surname><given-names>JN</given-names></name>, <etal>et al</etal>. (<year>2000</year>) <article-title>TLR4 mutations are associated with endotoxin hyporesponsiveness in humans</article-title>. <source>Nat Genet</source> <volume>25</volume>: <fpage>187</fpage>–<lpage>191</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Lindstrom1"><label>58</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lindstrom</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hunter</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Gronberg</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Stattin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Wiklund</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2010</year>) <article-title>Sequence variants in the TLR4 and TLR6-1-10 genes and prostate cancer risk. Results based on pooled analysis from three independent studies</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source> <volume>19</volume>: <fpage>873</fpage>–<lpage>876</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-CastanoRodriguez1"><label>59</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Castano-Rodriguez</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Kaakoush</surname><given-names>NO</given-names></name>, <name name-style="western"><surname>Goh</surname><given-names>KL</given-names></name>, <name name-style="western"><surname>Fock</surname><given-names>KM</given-names></name>, <name name-style="western"><surname>Mitchell</surname><given-names>HM</given-names></name> (<year>2013</year>) <article-title>The role of TLR2, TLR4 and CD14 genetic polymorphisms in gastric carcinogenesis: a case-control study and meta-analysis</article-title>. <source>PLoS One</source> <volume>8</volume>: <fpage>e60327</fpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Zhang1"><label>60</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhang</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Rao</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name> (<year>2013</year>) <article-title>The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis</article-title>. <source>Eur J Cancer</source> <volume>49</volume>: <fpage>946</fpage>–<lpage>954</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Su1"><label>61</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Su</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ceponis</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Lebel</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Huynh</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sherman</surname><given-names>PM</given-names></name> (<year>2003</year>) <article-title>Helicobacter pylori activates Toll-like receptor 4 expression in gastrointestinal epithelial cells</article-title>. <source>Infect Immun</source> <volume>71</volume>: <fpage>3496</fpage>–<lpage>3502</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Wroblewski1"><label>62</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Wroblewski</surname><given-names>LE</given-names></name>, <name name-style="western"><surname>Peek</surname><given-names>RM</given-names><suffix>Jr</suffix></name> (<year>2013</year>) <article-title>Helicobacter pylori in gastric carcinogenesis: mechanisms</article-title>. <source>Gastroenterol Clin North Am</source> <volume>42</volume>: <fpage>285</fpage>–<lpage>298</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Liu1"><label>63</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Wu</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <etal>et al</etal>. (<year>2011</year>) <article-title>Association of candidate genetic variations with gastric cardia adenocarcinoma in Chinese population: a multiple interaction analysis</article-title>. <source>Carcinogenesis</source> <volume>32</volume>: <fpage>336</fpage>–<lpage>342</lpage>.</mixed-citation>
</ref>
<ref id="pone.0082858-Zhong1"><label>64</label>
<mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Zhong</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Zou</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Sheng</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>B</given-names></name>, <etal>et al</etal>. (<year>2013</year>) <article-title>Genetic variations in the TGFbeta signaling pathway, smoking and risk of colorectal cancer in a Chinese population</article-title>. <source>Carcinogenesis</source> <volume>34</volume>: <fpage>936</fpage>–<lpage>942</lpage>.</mixed-citation>
</ref>
</ref-list></back>
</article>